Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention : Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein–Barr virus - 21/06/19
Abstract |
In 1964, the first human oncovirus, Epstein–Barr virus, was identified in Burkitt lymphoma cells. Since then, 6 other human oncoviruses have been identified: human papillomavirus, Merkel cell polyomavirus, hepatitis B and C viruses, human T-cell lymphotropic virus-1, and human herpesvirus-8. These viruses are causally linked to 12% of all cancers, many of which have mucocutaneous manifestations. In addition, oncoviruses are associated with multiple benign mucocutaneous diseases. Research regarding the pathogenic mechanisms of oncoviruses and virus-specific treatment and prevention is rapidly evolving. Preventative vaccines for human papillomavirus and hepatitis B virus are already available. This review discusses the mucocutaneous manifestations, pathogenesis, diagnosis, treatment, and prevention of oncovirus-related diseases. The first article in this continuing medical education series focuses on diseases associated with human papillomavirus and Merkel cell polyomavirus, while the second article in the series focuses on diseases associated with hepatitis B and C viruses, human T-cell lymphotropic virus-1, human herpesvirus-8, and Epstein–Barr virus.
Le texte complet de cet article est disponible en PDF.Key words : adult T-cell leukemia/lymphoma, Epstein–Barr virus, hepatitis B virus, hepatitis C virus, hepatocellular carcinoma, human herpesvirus-8, human T-cell lymphotropic virus-1, Kaposi sarcoma, oncovirus
Abbreviations used : ATLL, DAA, EBV, FDA, GCS, HBV, HCC, HCV, HHV-8, HPV, HTLV-1, IDH, KS, LMP, LP, LPD, MC, NA, NAE, PAN, PCT, peg-IFN, PTLD, SSLR, UROD
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
|
Date of release: July 2019 |
|
Expiration date: July 2022 |
Vol 81 - N° 1
P. 23-41 - juillet 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?